# Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir

> **NCT06356194** · PHASE1 · COMPLETED · sponsor: **Atea Pharmaceuticals, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Healthy Volunteer Study

## Interventions

- **DRUG:** Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK
- **DRUG:** Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered.

## Key facts

- **NCT ID:** NCT06356194
- **Lead sponsor:** Atea Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-15
- **Primary completion:** 2024-05-30
- **Final completion:** 2024-05-30
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06356194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06356194, "Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06356194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*